Mar 7, 2022 · 52m · capital-allocators
Annie Lamont – A Lifetime in Venture, Venture is Eating the Investment World 9 (Capital Allocators, EP. 238)
gold bands on the timeline = statements, start to end. Hover to read, click to jump. CC turns on captions
In this episode of Capital Allocators, host Ted Seides interviews Oak HC/FT Co-Founder Annie Lamont, exploring her 40-year venture capital career, specialized investment framework in healthcare and fintech, and strategies for navigating market cycles and building enduring platform companies.
How this conversation actually went
Every chapter scored 0–10 on four independent dynamics. Hover any point for the reasoning behind the score. Ted holds 26.5% of the talking time here. How this is scored →
speaking balance: gold is Ted, purple is the guest (3 minute bins)
Annie forcefully rejects the standard private equity reliance on Bain or McKinsey, insisting that true venture domain specialists must possess firsthand operational knowledge.
Hardest push from Ted ▶ 42:01 Ted presses on the risk of size eroding venture performanceTed directly confronts the classic venture paradox of whether growing fund assets dilutes returns and forces firms into indexing the market.
Biggest teaching moment ▶ 14:44 Annie explains the structural failure of early biotech investingAnnie educates Ted on the market reality of the early 2000s, explaining why thousands of public biotech companies had only five approved drugs and why Oak redirected capital into tech-enabled healthcare.
Ted holds their own ▶ 46:32 Ted challenges venture platform expansion as an unsustainable arms raceTed articulates the operational pitfalls of firms building sprawling global footprints and specialized support teams.
the scores for every segment, with the reasoning behind each
| Chapter | Topic | Ted as informed peer | Guest teaching | Guest disagreement | Ted pushing back | Why |
|---|---|---|---|---|---|---|
| Annie Lamont's Early Career and 1980s Venture Foundations | 4 | 5 | 1 | 1 | Ted prompts Annie to recount the nascent venture ecosystem of the 1980s and the structural differences between East Coast and West Coast investing. Annie shares historical color on taking Apple and Genentech public, setting a collaborative and reflective tone. | |
| The Primacy of CEO Quality and Team Building | 5 | 6 | 2 | 2 | Ted probes on how Annie assesses CEO quality and manages strategic market pivots across tech bubbles. Annie explains the discipline of stepping back from dry sectors like early biotech to pioneer healthcare software and payments. | |
| The Genesis and Spin-Out of Oak HC/FT | 5 | 5 | 1 | 2 | Ted asks about the mechanics and branding decisions behind spinning out Oak HC/FT while the legacy partnership phased out. Annie outlines the cultural imperative to build a dedicated value-add platform around talent and operators. | |
| Investment Focus and Intersection of Healthcare & FinTech | 5 | 6 | 2 | 2 | Ted inquires into sourcing pipelines and how early-stage trends inform growth investing. Annie explains why avoiding binary FDA risks while targeting the regulated convergence of fintech and healthcare generates proprietary deal flow. | |
| Diligence Execution and Operator Value Creation | 4 | 5 | 1 | 1 | Ted asks how Oak HC/FT conducts due diligence and deploys operational talent. Annie dismisses third-party consulting firms, asserting that decades of deep domain knowledge allow them to complete internal customer diligence directly. | |
| Valuation Discipline and Market Reset in Tech Investing | 5 | 6 | 2 | 2 | Ted examines how surging capital inflows have affected deal terms and valuations. Annie clarifies that while entry prices inflated, discipline shifts to assessing long-term exit durability amid macro public market pullbacks. | |
| Healthcare Innovation: Pay-Vider Models and Workflow Automation | 5 | 6 | 2 | 1 | Ted asks about core emerging themes in healthcare delivery. Annie breaks down the mechanics of the pay-vider model where providers take on capitation risk, alongside the acute post-pandemic demand for administrative automation. | |
| Virtual Care, Home-Based Medicine, and Caregiver Support | 4 | 5 | 1 | 1 | Ted asks about specific business models capitalizing on virtualization. Annie highlights home-based acute care and platforms that empower low-wage caregivers to reduce expensive institutional hospitalizations. | |
| FinTech Transformation and Digital Asset Infrastructure | 5 | 6 | 2 | 2 | Ted asks about Oak HC/FT's perspective on crypto and decentralized finance. Annie distinguishes between speculative token trading and enterprise digital asset infrastructure like Paxos. | |
| Fund Sizing, Brand Moats, and Market Share Dynamics | 6 | 6 | 2 | 3 | Ted challenges whether scaling fund sizes compromises returns or creates an index-like approach. Annie defends their concentrated fund sizing by pointing to inflated round sizes and the necessity of brand market share to win competitive deals. | |
| Cycle Navigation, Inorganic Growth, and Global Footprint | 6 | 5 | 2 | 3 | Ted asks if geographic expansion and platform additions risk triggering a venture arms race. Annie counters that maintaining a small, partner-heavy model with high liquidity turnover prevents overexpansion. | |
| Public Policy Insights as First Lady of Connecticut | 4 | 5 | 1 | 1 | Ted asks Annie about balancing her investing role with public service as First Lady of Connecticut. Annie explains how understanding state-level policy complements healthcare and fintech investing while fostering local entrepreneurship. |